Integrated profiling of basal and luminal breast cancers
- PMID: 18089785
- DOI: 10.1158/0008-5472.CAN-07-2536
Integrated profiling of basal and luminal breast cancers
Abstract
Basal and luminal are two molecular subtypes of breast cancer with opposite histoclinical features. We report a combined, high-resolution analysis of genome copy number and gene expression in primary basal and luminal breast cancers. First, we identified and compared genomic alterations in 45 basal and 48 luminal tumors by using 244K oligonucleotide array comparative genomic hybridization (aCGH). We found various genome gains and losses and rare high-level gene amplifications that may provide therapeutic targets. We show that gain of 10p is a new alteration in basal breast cancer and that a subregion of the 8p12 amplification is specific of luminal tumors. Rare high-level amplifications contained BCL2L2, CCNE, EGFR, FGFR2, IGF1R, NOTCH2, and PIK3CA. Potential gene breaks involved ETV6 and FLT3. Second, we analyzed both aCGH and gene expression profiles for 42 basal and 32 luminal breast cancers. The results support the existence of specific oncogenic pathways in basal and luminal breast cancers, involving several potential oncogenes and tumor suppressor genes (TSG). In basal tumors, 73 candidate oncogenes were identified in chromosome regions 1q21-23, 10p14, and 12p13 and 28 candidate TSG in regions 4q32-34 and 5q11-23. In luminal breast cancers, 33 potential oncogenes were identified in 1q21-23, 8p12-q21, 11q13, and 16p12-13 and 61 candidate TSG in 16q12-13, 16q22-24, and 17p13. HORMAD1 (P = 6.5 x 10(-5)) and ZNF703 (P = 7 x 10(-4)) were the most significant basal and luminal potential oncogenes, respectively. Finally, among 10p candidate oncogenes associated with basal subtype, we validated CDC123/C10orf7 protein as a basal marker.
Similar articles
-
An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.Carcinogenesis. 2008 Aug;29(8):1475-82. doi: 10.1093/carcin/bgn157. Epub 2008 Jul 1. Carcinogenesis. 2008. PMID: 18596026 Review.
-
Comparative genomic hybridisation arrays: high-throughput tools to determine targeted therapy in breast cancer.Pathobiology. 2008;75(2):63-74. doi: 10.1159/000123844. Epub 2008 Jun 10. Pathobiology. 2008. PMID: 18544961 Review.
-
DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.Genes Chromosomes Cancer. 2008 Jun;47(6):490-9. doi: 10.1002/gcc.20550. Genes Chromosomes Cancer. 2008. PMID: 18314908
-
Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q.Br J Cancer. 2006 Nov 20;95(10):1439-47. doi: 10.1038/sj.bjc.6603433. Epub 2006 Oct 24. Br J Cancer. 2006. PMID: 17060936 Free PMC article.
-
Detailed gene copy number and RNA expression analysis of the 17q12-23 region in primary breast cancers.Genes Chromosomes Cancer. 2003 Apr;36(4):382-92. doi: 10.1002/gcc.10138. Genes Chromosomes Cancer. 2003. PMID: 12619162
Cited by
-
A novel bioinformatic approach reveals cooperation between Cancer/Testis genes in basal-like breast tumors.Oncogene. 2024 May;43(18):1369-1385. doi: 10.1038/s41388-024-03002-7. Epub 2024 Mar 11. Oncogene. 2024. PMID: 38467851 Free PMC article.
-
ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines.Pharmaceutics. 2023 Jul 11;15(7):1930. doi: 10.3390/pharmaceutics15071930. Pharmaceutics. 2023. PMID: 37514116 Free PMC article.
-
Ectopically Expressed Meiosis-Specific Cancer Testis Antigen HORMAD1 Promotes Genomic Instability in Squamous Cell Carcinomas.Cells. 2023 Jun 14;12(12):1627. doi: 10.3390/cells12121627. Cells. 2023. PMID: 37371097 Free PMC article.
-
Divergent regulation of α-arrestin ARRDC3 function by ubiquitination.Mol Biol Cell. 2023 Aug 1;34(9):ar93. doi: 10.1091/mbc.E23-02-0055. Epub 2023 May 24. Mol Biol Cell. 2023. PMID: 37223976 Free PMC article.
-
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib.Front Oncol. 2023 Mar 17;13:1125021. doi: 10.3389/fonc.2023.1125021. eCollection 2023. Front Oncol. 2023. PMID: 37007122 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous